Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, June 21, 2018
[ Thu, Jun 21st 2018
] - WOPRAI
[ Thu, Jun 21st 2018
] - WOPRAI
[ Thu, Jun 21st 2018
] - WOPRAI
[ Thu, Jun 21st 2018
] - WOPRAI
[ Thu, Jun 21st 2018
] - WOPRAI
[ Thu, Jun 21st 2018
] - WOPRAI
[ Thu, Jun 21st 2018
] - WOPRAI
Wed, June 20, 2018
[ Wed, Jun 20th 2018
] - WOPRAI
[ Wed, Jun 20th 2018
] - WOPRAI
[ Wed, Jun 20th 2018
] - WOPRAI
[ Wed, Jun 20th 2018
] - WOPRAI
[ Wed, Jun 20th 2018
] - WOPRAI
[ Wed, Jun 20th 2018
] - WOPRAI
[ Wed, Jun 20th 2018
] - WOPRAI
[ Wed, Jun 20th 2018
] - WOPRAI
[ Wed, Jun 20th 2018
] - WOPRAI
[ Wed, Jun 20th 2018
] - WOPRAI
[ Wed, Jun 20th 2018
] - WOPRAI
Tue, June 19, 2018
[ Tue, Jun 19th 2018
] - WOPRAI
[ Tue, Jun 19th 2018
] - WOPRAI
[ Tue, Jun 19th 2018
] - WOPRAI
Josh Schimmer Upgraded (BLUE) to Buy and Increased Target to $230 on, Jun 19th, 2018
Josh Schimmer of Evercore ISI Group, Upgraded "bluebird bio, Inc." (BLUE) to Buy and Increased Target from $175 to $230 on, Jun 19th, 2018.
Josh has made no other calls on BLUE in the last 4 months.
There are 3 other peers that have a rating on BLUE. Out of the 3 peers that are also analyzing BLUE, 2 agree with Josh's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $209 on, Wednesday, March 21st, 2018
- Ying Huang of "B of A Securities" Maintained at Hold with Increased Target to $218 on, Thursday, February 22nd, 2018
This is the rating of the analyst that currently disagrees with Josh
- Matthew Luchini of "BMO Capital" Maintained at Buy with Decreased Target to $216 on, Thursday, May 3rd, 2018
